Abstract 36P
Background
Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLSs) rich in B cells. However, studies are still needed to better characterize cellular and molecular components of the TME the that could favor or hamper B cell organization in STS-associated TLSs.
Methods
The transcriptomic immune profiling of STS TME was performed using the Human Immunology V2 Panel and the NanoString nCounter platform on 33 STS biopsies or surgical samples. Patients with primary or locally recurrent STS were enrolled and treated at the Careggi Hospital (Florence, Italy; RESEARCH study). Results were validated by retrieving RNA-sequencing and clinical data for 164 STS patients from The Cancer Genome Atlas (TCGA) SARC project.
Results
We investigated the impact of gene signatures discriminating for specific immune cells and we found a significant association with relapse-free survival (RFS) only for germinal center (GC) B cell- and T helper 17 (Th17) cell-related signatures (p < 0.05). We observed a correlation between GC-B and Th17 signatures (r = 0.77, p < 0.0001), and the combination of both GC B and Th17 signatures was associated with better RFS, while low expression of both GC B and Th17 signatures was associated with the worst survival outcome (p = 0.035). The prognostic value of the GC-B/Th17 signature was confirmed on data from TCGA SARC project for both RFS (p = 0.016) and overall survival (p = 0.014). Differential gene expression analysis showed a more inflamed landscape in GC-B/Th17-high tumors. Conversely, the upregulation of genes encoding immunosuppressive molecules and genes related to tumor-associated macrophages with an immunosuppressive phenotype, were observed in GC-B/Th17-low tumors.
Conclusions
Our data identified a novel prognostic signature composed of GC B cell- and Th17 cell-related genes for STS patients, and suggest a potential collaboration between GC B cells and Th17 cells in mediating antitumor immune responses and potentially TLS formation in STS.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC
Presenter: Daqiang Sun
Session: Poster Display
80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)
Presenter: jun Tang
Session: Poster Display
81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)
Presenter: Marisa Bittoni
Session: Poster Display
82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display
84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study
Presenter: Ying Cheng
Session: Poster Display
85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Yun Fan
Session: Poster Display
86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis
Presenter: Yan Huang
Session: Poster Display
88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: MARA PERSANO
Session: Poster Display